ABVD regimen
E499490
The ABVD regimen is a standard chemotherapy combination used as first-line treatment for classical Hodgkin lymphoma.
All labels observed (2)
| Label | Occurrences |
|---|---|
| ABVD regimen canonical | 2 |
| ABVD chemotherapy regimen | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T5160992 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: ABVD regimen Context triple: [Hodgkin lymphoma, treatedWith, ABVD regimen]
-
A.
R-CHOP
R-CHOP is a standard chemotherapy regimen combining rituximab with multiple cytotoxic drugs, commonly used to treat non-Hodgkin lymphoma.
-
B.
Hodgkin
Hodgkin is a surname most famously associated with Dorothy Hodgkin, the Nobel Prize–winning British chemist who advanced the field of X-ray crystallography.
-
C.
Hodgkin lymphoma
Hodgkin lymphoma is a type of cancer that originates in the lymphatic system, characterized by the presence of abnormal Reed–Sternberg cells and often affecting lymph nodes.
-
D.
Rituxan
Rituxan is a monoclonal antibody drug (rituximab) widely used to treat certain blood cancers and autoimmune diseases by targeting the CD20 protein on B cells.
-
E.
Alimta
Alimta is a chemotherapy drug (pemetrexed) primarily used to treat malignant pleural mesothelioma and non-small cell lung cancer.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: ABVD regimen Target entity description: The ABVD regimen is a standard chemotherapy combination used as first-line treatment for classical Hodgkin lymphoma.
-
A.
R-CHOP
R-CHOP is a standard chemotherapy regimen combining rituximab with multiple cytotoxic drugs, commonly used to treat non-Hodgkin lymphoma.
-
B.
Hodgkin
Hodgkin is a surname most famously associated with Dorothy Hodgkin, the Nobel Prize–winning British chemist who advanced the field of X-ray crystallography.
-
C.
Hodgkin lymphoma
Hodgkin lymphoma is a type of cancer that originates in the lymphatic system, characterized by the presence of abnormal Reed–Sternberg cells and often affecting lymph nodes.
-
D.
Rituxan
Rituxan is a monoclonal antibody drug (rituximab) widely used to treat certain blood cancers and autoimmune diseases by targeting the CD20 protein on B cells.
-
E.
Alimta
Alimta is a chemotherapy drug (pemetrexed) primarily used to treat malignant pleural mesothelioma and non-small cell lung cancer.
- F. None of above. chosen
Statements (50)
| Predicate | Object |
|---|---|
| instanceOf |
chemotherapy regimen
ⓘ
combination chemotherapy ⓘ first-line treatment ⓘ |
| acronymFor |
Adriamycin
ⓘ
linked to:
adriamycin
Bleomycin ⓘ
linked to:
bleomycin
Dacarbazine ⓘ Vinblastine ⓘ |
| comparedWith |
BEACOPP regimen
ⓘ
Stanford V regimen ⓘ |
| contraindicatedIn |
severe cardiac dysfunction
ⓘ
severe pulmonary dysfunction ⓘ |
| developedAs | alternative to MOPP regimen ⓘ |
| drugClassIncluded |
alkylating agent
ⓘ
anthracycline ⓘ antitumor antibiotic ⓘ vinca alkaloid ⓘ |
| guidelineRecommendedBy |
ASCO
ⓘ
linked to:
American Society of Clinical Oncology
ESMO ⓘ NCCN ⓘ |
| hasAdministrationSetting | outpatient oncology clinic ⓘ |
| hasComponentDrug |
adriamycin
ⓘ
bleomycin ⓘ dacarbazine ⓘ doxorubicin ⓘ vinblastine ⓘ |
| hasRisk | infertility risk lower than MOPP ⓘ |
| hasToxicity |
alopecia
ⓘ
cardiotoxicity ⓘ myelosuppression ⓘ nausea and vomiting ⓘ peripheral neuropathy ⓘ pulmonary toxicity ⓘ |
| mayRequireDoseModificationIn |
hepatic impairment
ⓘ
renal impairment ⓘ |
| requiresMonitoringOf |
cardiac function
ⓘ
complete blood count ⓘ liver function tests ⓘ pulmonary function ⓘ renal function ⓘ |
| routeOfAdministration | intravenous ⓘ |
| standardOfCareFor | many newly diagnosed classical Hodgkin lymphoma patients ⓘ |
| treatmentIntent | curative ⓘ |
| typicalCycleLength | 28 days ⓘ |
| typicalNumberOfCycles | 2 to 6 cycles ⓘ |
| typicalSchedule | days 1 and 15 of a 28-day cycle ⓘ |
| usedFor |
Hodgkin lymphoma
ⓘ
classical Hodgkin lymphoma ⓘ |
| usedIn |
advanced-stage Hodgkin lymphoma
ⓘ
early-stage Hodgkin lymphoma ⓘ |
| usedInCombinationWith | involved-site radiotherapy ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: ABVD regimen Description of subject: The ABVD regimen is a standard chemotherapy combination used as first-line treatment for classical Hodgkin lymphoma.
Referenced by (3)
Full triples — surface form annotated when it differs from this entity's canonical label.
linked to: ABVD regimen